INmune Bio Inc (NASDAQ:INMB)
| 10.28 BATS BZX Real-Time Price As of 10:40am ET |  +0.03 / +0.29%Today’s Change | 2.20 Today|||52-Week Range 24.42 | +77.24% Year-to-Date |
Latest INMB News | Press Releases
| INmune Bio secures $2.9M funding to advance a mid-stage depression study with lead drug Sep 16 / Seeking Alpha - Paid Partner Content | INmune Bio receives patent for covering INKmune therapy Sep 03 / Seeking Alpha - Paid Partner Content |
| INmune Bio (INMB) Investor Presentation - Slideshow Sep 03 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 10.25 |
| Today’s open | 10.30 |
| Day’s range | 10.28 - 10.33 |
| Volume | 952 |
| Average volume (3 months) | 835,856 |
| Market cap | $149.1M |
Data as of 10:40am ET, 09/29/2020
Growth & Valuation
| Earnings growth (last year) | +41.48% |
| Earnings growth (this year) | -1.00% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 5.06 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| LCTXLineage Cell Therape... | +0.04 | +4.02% |
| EQEquillium Inc | -0.11 | -1.94% |
| DRIODarioHealth Corp | -0.15 | -0.85% |
| CFRXContraFect Corp | +0.03 | +0.57% |
Data as of 10:41am ET, 09/29/2020
Financials
| Next reporting date | November 6, 2020 |
| EPS forecast (this quarter) | -$0.17 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$7.7M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters La Jolla, California |
Forecasts
